Regarding “veterans affairs (VA) cooperative study #362”  by Tangelder, Marco J.D et al.
will spontaneously seal, and secondly, to see if these intrasac flow
velocities corresponded to the preoperative branch vessel anatomy
seen on the CT angiogram. The results indicated that patients with
occluded or small inferior mesenteric arteries and fewer visualized
lumbar arteries had lower intrasac flow velocities (100 cm/sec)
and these endoleaks resolved within 6 months.1 Thus, the study
used both anatomic data from the CT and physiologic data from
the Duplex US to characterize these endoleaks.
In reference to angle correction: a 60 degree angle to flow
was used with color Doppler serving as a guide to determine the
flow channel—the aortic wall was not used as a guide for this
measurement. Assessment of flow velocities and direction was
performed in the aneurysm sac near the aneurysm wall. Where
there is no angle to flow, as when sampling at or near the lumbar
orifice, no angle correction is needed as flow is perpendicular to the
Doppler beam in this situation.
We did not measure resistive index (RI) in this study. It is
unclear to us how an appropriate RI measurement could be ob-
tained from a “to and fro” signal often associated with type II
endoleaks. We look forward to further research efforts by the
endovascular community to validate and apply these to the clinical
management of the patient with type II endoleaks.
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Regarding “Veterans Affairs (VA) Cooperative Study
#362”
The Veterans Affairs (VA) Cooperative Study #362, reported
by Willard C. Johnson and colleagues (J Vasc Surg 2002;35:413-
21), did not demonstrate any difference in patency rate for warfarin
sodium (target range, 1.4-2.8 international normalized ratio
[INR]) plus aspirin (WASA) versus aspirin (ASA) in 458 patients
after peripheral venous bypass grafting. In 373 patients with
above-knee prosthetic bypass grafts, patency was significantly bet-
ter in the WASA group (risk ratio, 0.62). These results conflict with
our findings in the Dutch Bypass Oral Anticoagulants or Aspirin
(BOA) Study,1 favoring oral anticoagulant treatment after venous
bypass grafting and ASA in patients with prosthetic grafts. There-
fore we would like to highlight the two most important differences
in the design of the two trials and to discuss some differences in
results and the implications for daily practice.
First, the degree of anticoagulation was much higher in the
Dutch BOA study: target range, 3.0 to 4.5 INR. To achieve
optimal anticoagulation the target should be within this higher
range.2 The dosage of warfarin in the VA study was monitored
once a month, compared with twice a month, on average, in the
BOA study, which may have resulted in a higher proportion of time
when degree of coagulation was within the target range. There was
also a striking difference in percentage of patients who discontin-
ued anticoagulant treatment: 40% in the VA trial versus only 14% in
the Dutch BOA study. These differences in dosage and compliance
contribute considerably to the difference in antithrombotic effi-
cacy. The difference in ASA dose (325 mg/d in VA, 80 mg/d in
BOA) probably does not explain any difference in results.3
Second, the trials differed greatly in number of patients and
duration of follow-up. The sample size in the BOA study (n 
2690) was based on expected occlusion rate after average fol-
low-up of 2 years. The large number of patient-years (4560) in the
BOA study allowed for the predefined subgroup analyses accord-
ing to type of bypass procedure and graft material.4 The VA study
comprised fewer patients (831), with 2638 patient-years of follow-
up. Sample size was based on expected 6-year patency rate. Inas-
much as most occlusions occur in the first postoperative year, the
number of patients with 1-year follow-up in the VA Study was
probably too low to demonstrate a difference between the two
treatment groups.
It was surprising that the only statistically significant difference
between the two treatment groups occurred in patients with
prosthetic above-knee bypass grafts, and favored WASA. This
difference is mainly due to a higher number of occlusions in the
ASA group in the last 3 years of the study. Given the low compli-
ance with warfarin therapy, especially over the long term, and the
small number of patients (207) in this subgroup, this effect was
probably not caused by allocated treatment but by chance or other
unknown factors.
What are the implications of the VA and BOA trials for daily
practice? The common feature of both trials is the pragmatic
design, which allows generalization of the findings to daily prac-
tice. Because of a well-organized system of Dutch Anticoagulation
Clinics, anticoagulation therapy might be more effective in The
Netherlands than in the United States. This could imply that
addition of low-dose warfarin therapy to ASA treatment in the
United States has little or no effect, whereas in the Dutch health
care setting oral anticoagulant agents are more effective than ASA
for prevention of venous graft occlusion. For patients with pros-
thetic bypass grafts, ASA remains the best antithrombotic treat-
ment, worldwide.
The authors of the VA Study have improved knowledge of
antithrombotic therapy and discussed their findings clearly. We
hope to have added further clarification with our expertise and this
contribution to the discussion.
Marco J.D. Tangelder
Ale Algra
James Lawson
Hero van Urk
Bert C. Eikelboom
on behalf of the Steering Committee of the Dutch BOA Study
University Hospital Utrecht, Vascular Surgery/BOA Trial Office
Utrecht, The Netherlands
REFERENCES
1. The Dutch Bypass Oral Anticoagulants or Aspirin (BOA) Study Group.
Efficacy of oral anticoagulants compared with aspirin after infrainguinal
bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study):
a randomised trial. Lancet 2000;555:346-51.
2. Tangelder MJD, Algra A, Lawson JA, Hennekes S, Eikelboom BC, on
behalf of the Dutch BOA Study Group. Optimal oral anticoagulant
intensity to prevent secondary ischemic and hemorrhagic events in pa-
tients after infrainguinal bypass surgery. J Vasc Surg 2001;33:522-7.
3. Antiplatelet Trialists’ Collaboration. Collaborative overview of random-
ised trials of antiplatelet therapy. II: Maintenance of vascular graft or
arterial patency by antiplatelet therapy. BMJ 1994;308:159-68.
4. Dutch Bypass Oral Anticoagulants or Aspirin Study Group. Interpreta-
tion of Dutch BOA trial. Lancet 2000;355:1186-7.
doi:10.1016/S0741-5214(03)00469-5
Regarding “Rib-cross thoracotomy for replacement of
the thoracoabdominal or total descending aorta”
In a recent issue of this journal, Dr Okita and colleagues
reported their experience with four patients in whom rib-cross
thoracotomy was performed for repair of thoracoabdominal or
entire descending aortic aneurysm (J Vasc Surg 2003;37:219-21).
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